thymosin
alpha
acid
peptid
first
describ
character
calf
thymus
peptid
enhanc
tcell
dendrit
cell
dc
antibodi
respons
modul
cytokin
chemokin
product
block
steroidinduc
apoptosi
thymocyt
due
pleiotrop
biolog
activ
gain
increas
interest
recent
year
use
treatment
variou
diseas
clinic
accordingli
increas
need
product
peptid
far
use
clinic
synthes
use
solid
phase
peptid
synthesi
summar
genet
engin
method
produc
use
prokaryot
eukaryot
express
system
effect
biolog
product
increas
secret
cytokin
promot
lymphocyt
prolifer
investig
vitro
studi
open
possibl
biotechnolog
product
research
clinic
applic
thymosin
alpha
biolog
activ
peptid
consist
amino
acid
residu
first
describ
character
goldstein
et
al
research
process
began
studi
thymu
import
vital
organ
homeostat
mainten
peripher
immun
system
goldstein
et
al
first
isol
describ
lymphocytopoiet
factor
calf
thymu
term
thymosin
multipl
action
thymosin
immun
endocrin
central
nervou
system
revis
goldstein
badamchian
purif
factor
led
isol
heatstabl
acetoneinsolubl
prepar
term
thymosin
fraction
could
induc
cell
differenti
enhanc
immunolog
function
induc
apoptosi
neuroendocrin
tumor
cell
promis
result
seen
provid
scientif
rational
isol
character
molecul
respons
reconstitut
tcell
immun
henc
first
purifi
found
time
activ
evalu
vivo
vitro
asparaginyl
endopeptidas
cleavag
product
prothymosin
acid
nuclear
protein
consist
amino
acid
residu
highli
conserv
acid
peptid
ubiquit
exist
lymphoid
tissu
spleen
lymph
node
nonlymphoid
tissu
lung
kidney
brain
mainli
exist
thymu
gland
especi
thymic
epitheli
cell
interestingli
secret
modul
hormon
releas
factor
potent
biolog
respons
modifi
brm
intens
clinic
applic
first
random
doubleblind
phase
ii
trial
carri
schulof
et
al
administr
synthet
postradiotherapi
patient
nonsmal
cell
lung
cancer
exhibit
signific
improv
relapsefre
overal
surviv
pronounc
patient
nonbulki
tumor
clinic
trial
worldwid
treatment
sever
type
cancer
hepat
b
viru
hbv
hepat
c
viru
hcv
infect
connect
close
hepatocellular
carcinoma
hcc
addit
show
remark
effect
treatment
diseas
sever
sepsi
acut
respiratori
distress
syndrom
ard
sever
acut
respiratori
syndrom
sar
gastrointestin
system
infecti
disord
spontan
periton
individu
cirrhosi
extens
applic
increas
need
produc
larger
quantiti
keep
grow
clinic
demand
besid
isol
calf
thymu
bioactiv
obtain
solidphas
synthesi
genet
engin
current
use
clinic
entir
solidphas
synthes
polypeptid
chemic
featur
ident
human
recent
genet
engin
express
differ
host
includ
escherichia
coli
pichia
pastri
plant
attract
attent
due
potenti
produc
low
cost
bioactiv
review
briefli
describ
biolog
activ
discuss
current
applic
cancer
infecti
diseas
furthermor
summar
way
genet
engin
product
peptid
mayb
provid
conceptu
framework
futur
studi
improv
qualiti
yield
differ
field
research
clinic
applic
mani
studi
perform
identifi
immunoregulatori
activ
vitro
vivo
evid
shown
increas
effici
cell
matur
stimul
precursor
stem
cell
differenti
cell
balanc
cell
peripher
blood
mononuclear
cell
pbmc
stimul
natur
killer
nk
cell
cytotox
lymphocyt
cell
could
directli
kill
viral
infect
cell
activ
dendrit
cell
dc
abl
protect
immunocompromis
mice
death
caus
aspergillosi
stimul
signific
increas
led
decreas
cytokin
patient
chronic
hcv
besid
remark
decreas
sever
sever
acut
pancreat
neg
effect
serum
level
tumor
necrosi
factoralpha
also
upregul
specif
cytokin
receptor
highaffin
cytokin
receptor
activ
immunoeffector
cell
modul
cytokin
express
also
directli
exert
effect
target
cell
could
increas
express
mhc
tumor
antigen
directli
depress
viral
replic
increas
express
viral
antigen
surfac
targetinfect
cell
make
visibl
immun
system
less
prone
escap
immunosurveil
although
observ
potenti
immunoregulatori
effect
clearli
evid
clear
mechan
action
immun
system
report
could
directli
modul
express
cytokin
gene
mhc
class
mhc
class
ii
relat
gene
well
signific
number
new
gene
act
immun
system
regul
naylor
colleagu
demonstr
gene
major
histocompat
protein
costimulatori
molecul
chemokin
cytokin
receptor
upregul
cell
monocyt
expos
indic
multipl
target
immuneenhanc
activ
illustr
fig
stimul
intracellular
signal
pathway
includ
mitogenactiv
protein
kinas
mapk
transduct
pathway
receptorassoci
factor
signal
pathway
activ
ikappa
b
kinas
ikk
also
found
induc
express
via
pathway
pathway
share
mani
cytokin
predict
potenti
synergi
cytokin
abl
prime
dc
antifung
resist
tolllik
receptor
myeloid
differenti
factor
depend
signal
besid
dc
could
also
prime
activ
mapk
nfb
pathway
activ
plasmacytoid
dc
pdc
led
activ
interferon
regulatori
factor
promot
effector
path
shown
decreas
tumor
cell
growth
vitro
vivo
demonstr
therapeut
use
sever
type
cancer
tabl
observ
exhibit
antiprolif
effect
human
hepatoma
cell
lung
adenocarcinoma
cell
vitro
assay
explor
antimetastaticantitumor
activ
subcutan
inject
balbcmic
significantli
reduc
liver
lung
metastas
decreas
local
tumor
growth
moodi
et
al
investig
effect
mammari
carcinogenesi
fisher
rat
found
could
reduc
mammari
carcinoma
incid
prolong
surviv
time
anoth
breast
adenoma
model
increas
surviv
time
femal
antigen
transgen
mice
fisher
rat
remain
determin
whether
immun
respons
also
increas
antitumor
activ
effect
lung
adenoma
small
base
studi
proform
moodi
gave
daili
aj
mice
bear
lung
adenoma
may
fight
tumor
either
stimul
immun
system
directli
inhibit
prolifer
tumor
cell
combin
brm
chemotherapi
agent
also
display
good
effect
reduc
tumor
burden
progress
plasmidliposom
complex
contain
cdna
human
ifn
inject
icr
mice
dualgen
plasmidliposom
complex
show
stronger
inhibitori
effect
growth
tumor
singl
gene
ifn
might
attribut
indirect
addit
induct
apoptosi
tumor
cell
increas
express
ifn
colorect
cancer
model
combin
could
dramat
increas
surviv
rate
well
control
tumor
metastasi
similarli
compar
carmustin
bcnu
monotherapi
intraperiton
inject
bcnu
adult
long
evan
rat
bear
glioblastoma
could
significantli
lower
tumor
burden
increas
cure
rate
sinc
cascad
feedback
network
immun
respons
combin
immunoact
molecul
affect
differ
immun
effector
cell
result
stimul
immun
respons
significantli
stronger
evok
singl
treatment
could
contribut
help
explain
mechan
signific
combin
therapi
sever
report
show
protect
effect
oxid
damag
posit
influenc
liver
superoxid
dismutas
sod
glutathion
peroxidas
gshpx
activ
therebi
limit
free
radic
damag
hepat
tissu
similarli
report
could
amelior
streptozotocininduc
pancreat
lesion
diabet
reduc
malondialdehyd
mda
increas
gsh
level
enhanc
activ
sod
catalas
cat
suggest
treatment
could
greatli
enhanc
overal
antioxid
capabl
pancreat
tissu
possess
abil
influenc
central
nervou
system
modulatori
effect
excitatori
synapt
transmiss
cultur
hippocamp
neuron
document
similarli
combin
chemotherapeut
treat
cancer
could
prevent
patient
chemotherapyinduc
neurotox
moreov
potent
effect
promot
endotheli
cell
migrat
angiogenesi
well
wound
heal
patient
cancer
often
accompani
signific
defici
cellular
immun
addit
standard
treatment
cancer
usual
induc
signific
depress
immun
respons
demonstr
decreas
tumor
cell
growth
vitro
vivo
therapeut
effect
sever
type
cancer
advanc
lung
advanc
breast
cancer
combin
chemotherapi
could
prevent
patient
chemotherapyinduc
neurotox
phase
ii
multicent
random
openlabel
studi
differ
dose
level
combin
dacarbazin
dtic
chemotherapi
given
patient
stage
iv
melanoma
report
result
show
combin
therapi
tripl
overal
respons
rate
extend
overal
surviv
nearli
month
compar
patient
treat
dtic
combin
recent
patient
unresect
hcc
transarteri
chemoembol
tace
combin
result
numer
higher
rate
surviv
tumor
respons
includ
transplant
candidaci
fewer
bacteri
infect
tace
alon
obvious
signific
tumor
growth
inhibit
surviv
rate
increas
achiev
differ
human
tumor
model
combin
treatment
modal
conclud
combinatori
therapi
repres
one
import
mediat
effect
therapeut
strategi
tumor
key
focu
use
treat
cancer
futur
chronic
hbv
infect
seriou
clinic
problem
worldwid
distribut
potenti
advers
sequela
cirrhosi
hepatocellular
carcinoma
approv
treatment
hepat
b
mani
countri
worldwid
significantli
increas
virolog
respons
time
therapi
studi
evalu
efficaci
treatment
hbeagposit
hbeagneg
chronic
hepat
b
instanc
administ
either
mg
mg
japanes
patient
hbeagposit
chronic
hepat
b
show
hbeag
seroconvers
week
end
treatment
respect
similarli
administ
mg
chines
patient
hbeagneg
chronic
hepat
b
twice
weekli
show
complet
respons
defin
normal
alanin
transaminas
alt
undetect
hbv
dna
pcr
assay
patient
month
end
treatment
zhang
et
al
search
materi
differ
databas
analyz
eight
trial
use
meta
analysi
found
lamivudin
combin
treatment
particularli
promin
lamivudin
monotherapi
term
alt
normal
rate
virolog
respons
rate
hbeag
seroconvers
rate
convers
lee
et
al
reveal
combin
lamivudin
display
better
benefit
virolog
biochem
respons
lamivudin
monotherapi
mayb
small
trial
scale
led
diverg
result
monotherapi
seem
use
treat
hcv
infect
confirm
random
doubleblind
placebocontrol
trial
howev
combin
therapi
pegyl
interferon
could
effect
suppress
viral
replic
difficulttotreat
hepat
c
patient
addit
well
toler
signific
advers
effect
observ
approxim
treatmentna
hcv
patient
fail
achiev
sustain
virolog
respons
svp
standard
pegifn
ribavirin
therapi
tripl
combin
therapi
ribavirin
develop
prove
safe
effect
treatment
option
difficulttotreat
hcv
patient
refractori
prior
convent
treatment
human
immunodefici
viru
hiv
special
target
cell
express
macrophag
dc
cell
viru
becom
lymphotrop
begin
infect
cell
effici
follow
significantli
declin
antibodi
class
switch
furthermor
cell
stimul
effect
facilit
escap
viru
immun
control
collaps
whole
immun
system
sinc
signific
immun
respons
play
import
role
prevent
infect
human
hiv
thought
induct
strong
immun
respons
especi
ctl
respons
could
import
prevent
onset
acquir
immun
defici
syndrom
aid
one
studi
suggest
combin
zidovudin
azt
result
signific
increas
number
function
cell
reduct
hiv
titer
anoth
interest
find
provid
chadwick
et
al
studi
safeti
efficaci
combin
highli
activ
antiretrovir
therapi
haart
stimul
immun
reconstitut
result
demonstr
appear
well
toler
could
dramat
increas
level
signal
joint
cell
receptor
excis
circl
sjtrec
patient
advanc
hiv
diseas
howev
longer
treatment
durat
augment
immun
reconstitut
need
investig
natur
sourc
obtain
tini
quantiti
obtain
larger
amount
peptid
liter
ton
fresh
frozen
calf
thymu
tissu
aceton
requir
furthermor
heterogen
allergen
introduc
manufactur
process
limit
avail
research
medic
applic
solid
phase
synthesi
permit
scientist
synthes
purifi
allow
human
clinic
trial
advantag
simplic
eas
oper
gener
effici
lack
endotoxin
dna
contamin
howev
difficult
sequenc
bear
high
number
protect
group
requir
assembl
peptid
may
give
final
low
yield
insuffici
puriti
high
expens
recent
report
reveal
combin
sidechain
anchor
approach
hydrophil
total
pegbas
resin
facilit
synthesi
high
puriti
high
yield
advanc
genet
engin
bioactiv
express
prokaryot
eukaryot
express
system
costeffect
altern
approach
produc
biotechn
drug
product
includ
fusion
protein
concatem
produc
e
coli
p
pastori
plant
solubl
express
could
escap
refold
inclu
fig
construct
concatem
gene
tvector
contain
gene
red
digest
bamhixhoi
bgliixhoi
respect
digest
bglii
bamhi
two
fragment
ident
termini
could
ligat
dna
ligas
subsequ
form
new
sequenc
ggatct
could
digest
neither
bamhi
bglii
therefor
plasmid
contain
doubl
gene
construct
could
destroy
concatem
gene
repeat
construct
thu
plasmid
contain
concatem
gene
repeat
repetat
could
also
construct
interpret
refer
color
figur
legend
reader
refer
web
version
articl
sion
bodi
see
fig
isol
purif
high
puriti
difficult
appli
clinic
treatment
come
true
number
studi
use
genet
engin
gain
bioactiv
summar
follow
e
coli
one
earliest
wide
use
host
product
heterolog
protein
advantag
rapid
growth
express
easi
cultur
high
yield
howev
e
coli
system
choic
express
disulfid
rich
protein
protein
requir
posttransl
modif
characterist
small
molecular
weight
needless
posttransl
modif
suitabl
express
e
coli
system
sever
strategi
express
fusion
protein
concatem
use
e
coli
express
system
report
gener
small
peptid
difficult
overexpress
directli
e
coli
sinc
quickli
degrad
cellular
proteas
use
proteasedefici
host
strain
fusion
tag
histag
thioredoxin
help
avoid
nonspecif
proteolyt
degrad
facilit
purif
follow
approach
synthes
human
gene
insert
plasmid
induct
express
solubl
form
e
coli
proteasedefici
host
strain
compar
express
system
system
provid
highest
express
level
fusion
protein
amount
total
express
protein
furthermor
gene
insert
express
thioredoxin
e
coli
strain
proteolyt
cleavag
chemic
acetyl
result
purifi
reversedphas
highperform
liquid
chromatographi
rphplc
yield
mg
per
litr
bacteri
cultur
method
simpl
costeffect
suitabl
largescal
product
sinc
improv
control
tumor
growth
observ
tumorbear
mice
treat
high
dose
combin
therapi
perform
prove
effect
inhibit
tumor
growth
control
infecti
diseas
especi
immunocompromis
host
thu
express
fuse
molecul
brm
synergist
effect
investig
cbli
solubl
bcell
lymphocyt
stimul
amplifi
humor
respons
fuse
flexibl
linker
sequenc
express
e
coli
bifunct
lymphokin
use
treatment
variou
immunodefici
syndrom
serv
immunomodul
enhanc
host
respons
vaccin
fusion
protein
consensu
solubl
amount
total
protein
e
coli
show
higher
antivir
effect
activ
promot
lymphocyt
prolifer
similar
commerci
difficult
extract
purifi
ferment
broth
sinc
molecular
weight
small
concatem
strategi
mayb
partial
solv
problem
low
express
difficulti
purif
increas
size
target
molecul
concatem
gene
repeat
construct
accord
e
coli
codon
usag
prefer
ligat
express
vector
transform
e
coli
monom
success
releas
hydroxylamin
incis
concatem
purif
activ
promot
mice
splenic
lymphocyt
prolifer
approxim
ident
natur
intim
process
construct
concatem
gene
describ
fig
addit
concatem
gene
repeat
synthes
success
express
e
coli
solubl
form
preliminari
result
demonstr
concatem
protein
also
activ
stimul
mous
spleen
lymphocyt
prolifer
common
knowledg
e
coli
lack
effici
posttransl
modif
system
modifi
exogen
protein
howev
fang
et
al
found
fusion
protein
ribosom
protein
partli
n
acetyl
express
e
coli
modif
perform
rimj
n
termin
acetyltransferas
modifi
ribosom
protein
act
ribosom
assembl
factor
enlighten
us
fulli
acetyl
obtain
coexpress
rimj
howev
littl
known
pathway
fusion
protein
n
acetyl
previou
report
activ
none
partli
n
acetyl
similar
natur
one
illustr
n
acetyl
could
influenc
stabil
peptid
instead
bioactiv
vivo
base
research
find
conclud
suitabl
express
e
coli
express
system
improv
express
efficaci
follow
measur
may
meaning
choos
e
coli
usag
prefer
codon
ii
use
differ
promot
regul
express
iii
use
proteasedefici
host
strain
yeast
attract
host
product
heterolog
protein
provid
posttransl
modif
gener
stabl
cell
line
via
homolog
recombin
exampl
express
yeast
express
system
present
follow
chen
et
al
success
construct
effect
yeast
express
system
plasmid
transform
yeast
host
strain
express
system
could
improv
level
cell
balbc
mice
treat
cyclophosphamid
advanc
fusion
express
bmr
p
pastori
also
report
exhibit
synerg
effect
treatment
hepat
b
hepat
c
fusion
protein
link
differ
length
glyglyglyglys
n
n
express
p
pastori
exhibit
antivir
activ
immunomodulatori
activ
estim
vitro
thymopentin
act
immunomodulatori
factor
cancer
chemotherapi
also
potenti
chemotherapeut
agent
human
leukemia
therapi
howev
extrem
short
halflif
vivo
greatli
restrict
clinic
applic
sens
fusion
gene
synthes
insert
vector
express
p
pastri
research
team
fusion
peptid
display
higher
activ
promot
phagocytosi
macrophag
prolifer
kunm
mous
splenocyt
plant
also
use
product
form
monom
concatem
recent
concatem
gene
repeat
introduc
success
express
transgen
tomato
bioactiv
concatem
protein
stimul
prolifer
mice
splenic
lymphocyt
vitro
stronger
synthes
artifici
concatem
protein
express
e
coli
system
underli
reason
unclear
requir
investig
exampl
demonstr
bioactiv
obtain
genet
engin
great
effort
made
improv
qualiti
function
puriti
yield
product
expect
next
year
find
way
clinic
addit
immunomodulatori
activ
own
abil
influenc
central
nervou
system
regul
endocrin
system
like
due
pleiotrop
biolog
activ
either
alon
combin
treatment
strategi
broader
spectrum
applic
success
treatment
variou
diseas
clinic
chemic
synthesi
effect
way
produc
clinic
therapi
genet
engin
attract
altern
rout
express
bioactiv
present
offer
higher
puriti
compar
chemic
synthesi
recent
gene
express
concatem
fusion
protein
becom
major
research
focu
effect
strategi
facilit
purif
increas
product
reduc
product
cost
believ
rapid
develop
biotechnolog
may
allow
applic
product
obtain
genet
engin
clinic
futur
